Milestone Pharmaceuticals Inc
For the period ended Mar 31, 2024. Filed May 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 13, 2024
MIST$0.74-3.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets** (Unaudited)**
(in thousands of US dollars, except share data)
| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | | | |
| · March 31, 2024 · December 31, 2023 | ||||||
| Assets | | | | |||
| | | | | | | |
| Current assets · · · · | ||||||
| Cash and cash equivalents | | $10,131 | $13,760 | |||
| Short-term investments | | | 79,350 | | | 52,243 |
| Research and development tax credits receivable | | | 711 | | 643 | |
| Prepaid expenses | | | 2,362 | | 3,178 | |
| Other receivables | | | 1,413 | | 3,208 | |
| Total current assets | | | 93,967 | | 73,032 | |
| Operating lease right-of-use assets | | | 1,785 | | | 1,917 |
| Property and equipment | | | 249 | | 277 | |
| Total assets | | $96,001 | $75,226 | |||
| | | | | | | |
| Liabilities, and Shareholders' Equity | | | | |||
| | | | | | | |
| Current liabilities | | | | |||
| Accounts payable and accrued liabilities | | $3,575 | $6,680 | |||
| Operating lease liabilities | | | 555 | | 546 | |
| Total current liabilities | | | 4,130 | | 7,226 | |
| Operating lease liabilities, net of current portion | | | 1,306 | | 1,457 | |
| Senior secured convertible notes | | | 50,644 | | | 49,772 |
| Total liabilities | | | 56,080 | | 58,455 | |
| | | | | | | |
| | | | | | | |
| Shareholders’ Equity | | | | | ||
| Common shares, no par value, unlimited shares authorized 53,245,165 shares issued and outstanding as of March 31, 2024, 33,483,111 shares issued and outstanding as of December 31, 2023 | | | 287,879 | | 260,504 | |
| Pre-funded warrants - 12,910,590 issued and outstanding as of March 31, 2024 and 9,577,257 as of December 31, 2023 | | | 53,076 | | | 48,459 |
| Additional paid-in capital | | | 35,346 | | 33,834 | |
| Accumulated deficit | | | (336,380) | | (326,026) | |
| | | | | | | |
| Total shareholders’ equity | | | 39,921 | | 16,771 | |
| | | | | | | |
| Total liabilities and shareholders’ equity | | $96,001 | $75,226 | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.